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Abstract
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B-1 lymphocytes exhibit unique phenotypic, ontogenic, and functional characteristics that differ
from the conventional B-2 cells. B-1 cells spontaneously secrete germline-like, repertoire skewed
polyreactive natural antibody, which acts as a first line of defense by neutralizing a wide range of
pathogens before launching of the adaptive immune response. Immunomodulatory molecules,
such as interleukin-10 (IL-10), adenosine, granulocyte-macrophage colony-stimulating factor
(GM-CSF), IL-3, and IL-35 are also produced by B-1 cells in the presence or absence of
stimulation, which regulate acute and chronic inflammatory diseases. Considerable progress has
been made during the past three decades since the discovery of B-1 cells, which has not only
improved our understanding of their phenotypic and ontogenic uniqueness but also their role in
various inflammatory diseases including influenza, pneumonia, sepsis, atherosclerosis,
inflammatory bowel disease (IBD), autoimmunity, obesity and diabetes mellitus. Recent
identification of human B-1 cells widens the scope of this field, leading to novel innovations that
can be implemented from bench to bedside. Among the vast number of studies on B-1 cells, we
have carried out a literature review highlighting current trends in the study of B-1 cell involvement
during inflammation, which may result in a paradigm shift towards sustainable therapeutics in
various inflammatory diseases.
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Introduction
Inflammation accompanies the body’s immune response. An inadequate response may lead
to a lack of clearance of invading organisms, whereas a hyper immune response could cause
tissue damage, and even death of the host [1]. Immediately after the host encounters a
pathogen, the innate immune system consisting of neutrophils, macrophages, dendritic cells,
natural killer (NK) cells, and circulating proteins becomes active to confer protection. In
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contrast, the adaptive immune system, which includes antibodies (Abs) produced by Blymphocytes and T-cell-mediated immunity becomes responsive at a later time point [1].
Although a large proportion of mature B-cells are primarily responsible for mediating
adaptive immunity via Ab production, B-cells also contribute to innate immunity and exhibit
critical immunoregulatory roles. For the purpose of this review, we will focus on B-1a cells
unless otherwise mentioned.
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In mice, mature B-cells consist of three major subsets: i) follicular B-cells, also known as
B-2 cells, located in lymphoid follicles, ii) marginal zone (MZ) B-cells localized proximal to
the marginal sinus of the spleen, and iii) B-1 cells most abundant in peritoneal and pleural
cavities [5, 6]. B-2 cells mount Ab responses in a T-cell-dependent manner, while both MZ
B-cells and B-1 cells generate T-cell-independent responses [6]. Depending on the presence
or absence of surface CD5, a pan T-cell marker, B-1 cells can be further subdivided into
B-1a (CD5+) and B-1b (CD5−) populations [7]. A growing body of evidence supports
considering B-1 cells to be a part of the innate immune system, whereas B-2 cells function
primarily in adaptive immune responses [6, 8].

Author Manuscript

Murine B-1a cells spontaneously secrete and maintain steady-state levels of natural Abs of
the immunoglobulin M (IgM) isotype in naïve, non-immunized, and antigen-free mice
[reviewed in 9]. B-1a cell-derived natural Abs are found to counteract a wide range of viral
and bacterial infections [10]. Recently, a specific role for B-1b cells in generating long
lasting immunity to the relapsing fever bacterium B. hermsii has also been demonstrated
[11]. This is consistent with other evidence that to combat pathogens B-1a cells secrete
natural Abs that protect against infection or lower bacterial burden if infection is established;
whereas, B-1b cells secrete induced antibody needed to clear certain bacteria and permit
survival [12, 13]. The natural Abs secreted from B-1a cells not only neutralize invading
pathogens but also recognize and clear dying cells leading to suppression of uncontrolled
inflammation and autoimmunity [9].
Soon after the discovery of B-1 cells in mice [5], a number of studies demonstrated their role
in various inflammatory diseases. Our current review encompasses the latest trends of B-1
cell pathobiology by revisiting its immunomodulatory functions in terms of natural Ab
secretion, antigen presentation, phagocytosis, T-cell polarization, and immune suppression
in order to help define the therapeutic potential of B-1 cells during inflammation.

B-1 cells: A brief overview
Phenotype and localization

Author Manuscript

B-1 cells comprise a minor portion of the total B-cells in mice and display unique features in
terms of their surface phenotype, localization, ontogenesis, and function [5, 7, 8, 12, 14–16].
The cell surface phenotype of murine B-1 cells is CD45R(B220)lo, surface IgM (sIgM)hi,
sIgDlo, CD23lo/−, CD19hi and CD43+, and can be either CD5+ (B-1a) or CD5− (B-1b) [7,
17, 18]. B-1a cells are predominantly localized in the peritoneal cavity, which accounts for a
major portion of the total B-cells of this compartment. B-1a cells are also found in spleen,
pleural cavity, and bone marrow, but are barely detectable in the blood and lymph nodes [5,
17, 19, 20]. Most of the B-1a cells in the peritoneal and pleural cavities express CD11b, a
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macrophage/granulocyte marker; however, the majority of the B-1a cells in spleen do not
express this marker [15, 17].
Ontogeny and development

Author Manuscript

B-1a cells represent a distinct developmental lineage derived from a unique progenitor
found in the fetal liver as well as in fetal and adult bone marrow [21]. The discovery of a
B-1 cell specific progenitor resolved the long lasting origin debate on lineage versus
differentiation concepts [reviewed in 22, 23]. Transfer of the B-1 cell progenitor
(Lineage−(Lin−)B220lo/−CD19+) into immunodeficient recipients efficiently reconstituted
B-1a and B-1b cells [21]. B-1 cell progenitors do not express syndecan-1 (CD138) or major
histocompatibility complex (MHC) class II Ags [24]. B-1 cell progenitors first appear in the
fetal liver around day-11 of gestation, at which time no CD45R+ B-2 progenitor cells are
observed. Similarly, no CD45R+ cells are observed in fetal bone marrow from embryonic
day-15, while the CD45R−/loCD19+ population is well detected [21].

Author Manuscript

The development of B-1 cells depends on IL-7Rα and Flt-3 ligand and is negatively
regulated by Bruton’s tyrosine kinase (Btk) [25, 26]. Recently, it has been shown B-1a cells
can also be generated by adult bone marrow [27, 28] and B-1 cell specific progenitors are
found in adult bone marrow [21]. However, the extent to which input from adult bone
marrow into the adult B-1a cell pool occurs is still being investigated. In adulthood, the B-1a
cell pool is primarily maintained by self-renewal, in which mature, surface Ig-bearing B-1
cells give rise to their own progeny [25]. Circulating B-2 B-cells by contrast generally lack
the ability to self-renew and are instead replenished by proliferative cells in the bone
marrow [25, 26]. The exclusive ability of B-1a cells to self-renew is supported by the
finding that these cells constitutively phosphorylate activated signal transducer and activator
of transcription 3 (STAT3), which may play a key role in positively regulating cyclin D2
expression that contributes to the proliferation of these cells [8, 25, 29]. The expansion of
B-1a cells has been shown to be controlled at least in part by Siglec-G, which is a cellinhibiting receptor that inhibits calcium signaling and nuclear factor-κB (NF-κB) activation
[30]. In addition to Siglec-G, CD22, another co-inhibitory receptor, has also been shown to
inhibit the proliferation of B-1 cells [31]. All together these findings demonstrate B-1a cells
appear early in the life as a developmentally separate and distinct lineage.
B-1 cell function

Author Manuscript

The main function of B-1a cells in the innate immune system is spontaneous secretion of
natural Abs, thereby maintaining resting immunoglobulin levels in the body without any
stimulus or immunization [9]. Natural Abs form a pre-existing shield against infection
providing protection during the period of time required for germinal center formation and
production of adaptive Abs. It has been estimated that 80–90% of resting serum IgM, and
50% of serum IgA is derived from B-1a cells [reviewed in 32]. Natural IgM that
accumulates in the serum is produced by B-1 cells residing in the spleen and bone marrow
[9, 33]. It has been shown that in animals treated with endotoxin, peritoneal B-1a cells
migrate to the spleen where they secrete higher amounts of Abs [34, 35]. The natural Abs
produced by B-1a cells differ from B-2 cell adaptive Abs in that they display little or no
somatic hypermutation and minimal N-region addition, thus reflecting germline sequences
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[33, 36]. Murine B-1a cell natural Abs are characteristically repertoire skewed, low affinity,
and polyreactive. B-1a cell-derived natural Abs are able to recognize phosphorylcholine
(PC), an invariant constituent of Gram positive microbial membranes such as the S.
pneumonia bacterial cell wall, as well as membranes of other bacterial pathogens, apoptotic
cell membranes, and oxidized lipids [9, 32]. In addition, natural Abs produced by B-1a cells
recognize phosphatidylcholine (PtC), a key constituent of senescent red blood cell
membranes [37]. Interaction of such natural Abs with an infectious agent can act either by
direct inhibition, complement activation, or opsonization leading to phagocytosis and/or Abdependent cell-mediated cytotoxicity [9, 32]. Natural Abs from B-1a cells are often
autoreactive and help eliminate dead cells and their debris [38]. In so doing, potentially
noxious molecules are removed before tissue injury can occur as a result of uncontrolled
immune cell activation.

Author Manuscript

Apart from natural IgM, B-1a cells also spontaneously secrete IL-10 and, after stimulation
with lipopolysaccharides (LPS), secrete GM-CSF and IL-3 [2, 3]. In addition, B-1a cells are
efficient antigen presenting cells, providing effective signaling to T-cells via co-stimulatory
molecules CD80/CD86, which are constitutively expressed on B-1a cells [9, 32, 39].
Furthermore, B-1a cells are able to induce T-cell proliferation and help induce CD4 T-cell
differentiation to pro-inflammatory Th17 cells [40].

B-1-related cells and subsets in innate immunity

Author Manuscript

B-1a cells are part of the innate immune system, as noted above. Some functions of B-1a
cells are segregated to a greater or lesser extent within particular subsets of B-1a cells
defined by phenotypic markers, such as PD-L2, CD73 and PC-1. In addition, several other B
cell subsets manifest activities that overlap with B-1a cells, including B10 cells, Breg cells
and IRA B cells.
Regulatory B (Breg) cells/B10-cells

Author Manuscript

In the early 90s it was reported that mouse peritoneal CD5+ B-1a cells are the major source
of IL-10, especially in the absence of stimulation, which raised the possibility of these cells
having immunoregulatory properties [45]. The term ‘regulatory B-cells or Breg cells’ was
coined in 2006 representing a specific subset of B-cells with immunoregulatory functions
[46]. This Breg cell subset has more recently been labeled B10 cells. B10 cells are able to
downregulate innate immune responses [47]. Currently, there are no phenotypic,
transcription factors, or lineage markers that are unique to B10 cells, although the majority
appear to correspond to B-1 cells. Therefore, B10 cells in mice and humans are functionally
defined and enumerated by their competence to express measurable IL-10 following ex vivo
stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin [2, 48]. B10 cells
are predominantly found within the spleen and peritoneal cavity and are also present in
small numbers within blood, lymph nodes, Peyer’s patches, and intestinal tissues [2, 48, 49].
The generalized ex vivo phenotype of B10 cells from untreated mice is
IgMhiIgDloCD1dhiCD5+CD19hiCD23loB220hi, with <10% co-expressing IgG or IgA [2, 48,
50].
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B-cells have been shown to produce several cytokines and growth factors both in vitro and
in vivo. Recently, Rauch et al. identified a novel B-cell population which expresses GMCSF upon LPS stimulation via the toll-like receptor-4 (TLR-4) pathway [51]. These cells
comprise 1–4% of the total B-cell population in spleen after stimulation and are termed
innate response activator (IRA) B-cells [51]. In another study, Weber et al demonstrated the
ability of IRA B-cells to produce IL-3 if stimulated with LPS, which might play a critical
role in emergency myelopoesis and acute inflammation [52]. Like B-1a cells, IRA B-cells
are also capable of producing an adequate amount of IgM when stimulated with LPS. The
surface phenotype of these cells was identified as
CD19+B220+IgM+MHCII+CD5+CD43+CD93+CD138+VLA4+CD284hiIgD+CD23+ CD21lo
but negative for CD11b, CD3, Ly-6G, Ly-6C, NK1.1, CD49b, Ter119, CD4, CD8, CD11c
[51]. After performing adoptive fate mapping and parabiosis experiments using mice lacking
B-cells and several innate signaling molecules, IRA B-cells were shown to be derived from
peritoneal B-1a B-cells that relocated to the spleen after recognizing LPS with TLR-4 [51].
Transcriptome analysis of IRA B-cells and comparison to other B-cell subsets revealed that
IRA B-cells are mainly located in serosal sites, have self-renewal ability, and appear early
during embryonic life [51].
PD-L2-expressing B-1a cells
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Interaction of the programmed death-1 receptor (PD-1) with its ligand programmed deathligand 1 (PD-L1) downmodulates lymphocyte activity, implying a role for PD-1 in
regulating autoimmunity as well as immune responses to viral and parasitic infections [53,
54]. Like T-cells and myeloid cells, B-cells also express PD-1, engagement of which by its
ligand(s) negatively regulates B-cell activity [55]. In studying the PD-1 pathway in B-1a
cell-mediated immunity, Zhong et al. found approximately 50–70% of resting peritoneal
B-1a cells express PD-L2 (CD273, B7-DC), a second PD-1 ligand, which was not present or
inducible on conventional B-2 cells [39]. This extended the range of PD-L2 expression and
showed that it is constitutively expressed in B-cells unlike inducible expression in other cell
types. Although PD-L2+ and PD-L2” B-1a cells are similar in proliferative responses and
spontaneous immunoglobulin secretion, PD-L2+ B-1a cells are highly enriched for
expression of VH11 and VH12 genes and represent the bulk of PtC-binding B-1 cells [39,
56]. Moreover, PD-L2+ B-1a cells are highly enriched for autoreactive specificities. These
findings show B-1 cells identified by PD-L2 express a specific repertoire.
CD73-expressing B-1a cells
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In a recent study, a novel subset of B-1a cells expressing CD73 as well as CD39, two
ectoenzymes that together catalyze the extracellular dephosphorylation of adenine
nucleotides to adenosine, has been identified and shown to play an immunomodulatory role
during inflammation [57]. Approximately 30–50% of total B-1 cells express high levels of
CD73, whereas only a very minor portion of conventional B-2 cells express very low levels
of CD73 [57]. Although extracellular adenosine triphosphate (ATP) is known to play a
proinflammatory role, its dephosphorylated form adenosine is immunosuppressive [58].
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Therefore, regulating the balance of extracellular ATP and adenosine, controlled at least in
part by CD73+ B-1a cells, is important in maintaining immune homeostasis.
PC1-expressing B-1a cells

Author Manuscript

The two classic functions of B-1a cells, i) innate-like and ii) immunoregulatory can be
segregated between two unique subsets based on the expression of plasma cell alloantigen 1
(PC1), also known as ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), an
enzyme involved primarily in the hydrolysis of ATP at the cell surface [59]. These subsets,
designated B-1a.PC1lo and B-1a.PC1hi, express distinct IgH repertoires and contribute to
varied levels of serum and mucosal natural Abs [59]. Adoptively transferred PC1lo cells
secreted significantly higher amount of circulating natural IgM and intestinal IgA than PC1hi
cells [59]. In contrast, the PC1hi cells produced more IL-10 than PC1lo cells when stimulated
with LPS and PMA and were able to regulate Th1 cell differentiation. Furthermore, PC1lo
cells generated antigen-specific IgM responses to pneumococcal polysaccharide antigens,
whereas PC1hi cells did not. Developmentally PC1lo cells arise from an early period of B-1a
progenitors in fetal life, whereas PC1hi cells are generated at a later time after birth [59].
Therefore, identification of B-1a.PC1lo and B-1a.PC1hi cells extends our understanding of
innate immune and immunoregulatory functions mediated by B-1a cells.

Human B-1 cells
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The presence of the CD5 antigen on B-cells generating autoantibodies in rheumatoid
arthritis patients was first considered to be the identifying marker of human B-1 cells [60,
61]. However, CD5 is also variably present on cells of several different human B-cell
populations, including activated, transitional, and pre-naive B-cells, which raised doubts
about the phenotypic designation of human B-1 cells in terms of the CD5 antigen [62–64].
As a result, confusion regarding the very existence of B-1 or B-1-like cells in the human
system remained. Recently, the nature of human B-1 cells was revisited by Griffin et al. who
identified a population of B-cells in human umbilical cord and peripheral blood that
manifested three key functional features of mouse B-1a cells [65]. These functional features
include: i) spontaneous immunoglobulin secretion, ii) constitutive intracellular signaling,
and iii) efficient T-cell stimulation. This population of human B-1 cells was defined as
CD20+CD27+CD43+ with little to no surface CD69 and CD70, which are both markedly upregulated after activation of CD20+CD27−CD43−(naive) and CD20+CD27+CD43−
(memory) B-cells [65, 66]. Identification of human B-1 cells will provide valuable insights
for future studies on the role of these cells in human inflammatory diseases. A summary of
B-1 cells, B-1 cells subsets, and related B-cells, in terms of phenotype, localization and
function is provided in Table 1.

B-1 cells and inflammation
Inflammation refers to the host response to invading pathogens mediated by both the innate
and adaptive arms of the immune system. B-1a cells are considered to be part of the innate
immune system, whereas B-2 cells primarily act in the adaptive immune system [8]. Recent
progress has been made towards elucidation of the role B-1a cells in various inflammatory
and autoimmune diseases, which is summarized in this review.
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Infection by influenza virus is the most common cause of human respiratory disease [67].
The virus spontaneously manipulates its surface proteins to generate highly variable
epitopes, thereby making it difficult to design broadly effective vaccines against influenza
virus. The polyreactive nature of B-1a cell-secreted natural Abs enables them to effectively
eliminate the influenza virus infection in mice [68, 69]. According to the recent studies,
systemic natural IgM secreted by B-1a cells is transported to mucosal surfaces through the
poly-Ig receptor leading to protection against influenza virus infection [68, 69]. The
importance of systemic natural IgM for protection against influenza virus has been
documented in mice deficient in secreted IgM but normal for surface bound IgM (sIgM),
which exhibited reduced clearance of virus and increased mortality following influenza virus
infection [69].
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Recent findings demonstrate an active role for B-1a cells which provides enhanced local
rather than systemic defense against influenza virus [70]. This defense was shown to be
mediated through highly localized activation of B-1a cells at lymph nodes close to the
respiratory tract, serving as a major source of local virus-neutralizing natural IgM [70].
Surface expression of the CD5 antigen in B-1a cells plays an important role in regulating
antigen driven B-cell receptor (BCR)-mediated signaling [71]. During influenza virus
infection CD5+ B-1a cell oriented active responses are not dependent on antigen-induced
BCR mediated proliferation but are mainly generated by their increased accumulation at the
lungs and its related lymph nodes as a result of their translocation from serosal cavities
where they spontenously secrete natural Abs and other immunomodulatory molecules to
confer protection against influenza virus infection [70, 71]. B-1b or conventional B-2-cells
on the other hand provide protection against pathogens through steps involving clonal
expansion via BCR-mediated signals in the absence of CD5 receptor on their surfaces [11].
In some cases of infection, B-1a cell-mediated immune regulation may not be beneficial. A
recent study revealed Xid mice deficient in B-1a cells showed better protection than normal
animals following infection with a virulent strain of F. tularensis [72]. The poor
performance by normal mice could be the result of B-1a cell generated IL-10 creating an
immunosuppressive environment in which virulent strains could more easily be replicated
rather than destroyed [72], a situation relieved in the absence of B-1a cells. Therefore, a
finely tuned balance between B-1a mechanisms promoting immune defense and immune
suppression is required for efficient viral clearance and recovery from infection.
S. pneumonia infection
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S. pneumoniae causes acute bacterial infection especially in the lungs. Approximately
400,000 hospitalizations from pneumococcal pneumonia infection are estimated to occur
annually in the United States, leading to 5%-7% case-fatality, which is significantly higher
among elderly persons [73]. With germline-like IgM and a distinctly skewed repertoire,
B-1a cell-derived natural IgM defends against bacterial infections. In particular, anti-PC Ab
derived from B-1a cells has been well characterized and shown to be protective against S.
pneumoniae infection [12, 74, 75]. The importance of anti-PC and anti-pneumococcal
capsular polysaccharide 3 (PPS3) germline-like natural Abs was shown in mice lacking
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B-1a cells, as they were unable to survive acute infection with S. pneumoniae [12]. The
polyreactive nature of natural IgM sometimes may not be able to effectively neutralize
certain invading pathogens. N-addition has been shown to play a key role in antigen receptor
diversity and Ab effectiveness to certain pathogens such as S. pneumoniae. B-1a cells also
secrete the prototypical anti-PC antibody, T15, which has no N-addition and is completely
germline [75, 76]. Terminal deoxytransferase (TdT) adds non templated nucleotides (Naddition) to the V-D and D-J junctions during antibody gene recombination, increasing
junctional diversity. Interestingly, in mice overexpressing TdT, vaccination with heat-killed
S. pneumoniae generated an anti-PC response, but these anti-PC antibodies were not
protective against S. pneumoniae infection [77]. This study demonstrates that excessive
diversity generated by N-addition can be detrimental for microbial protection.
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Utilizing various animal models of acute lung infection by direct intratracheal or intranasal
delivery of LPS, E. coli or S. pneumoniae Weber, et al. showed B-1a B-cells migrate from
the pleural space to the lung parenchyma and secrete GM-CSF and polyreactive IgM to
confer protection against infection [78]. Such a migration model has also been proposed by
Baumgarth et al, which suggests that body cavity B-1a cells circulate throughout the animal
in the steady state [79]. Following infection by pathogens, innate inflammatory signals
contribute to behavioral changes of B-1a cells in the body cavities and these responder
populations migrate to neighboring lymphoid sites [79].
Sepsis
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Sepsis is a pervasive human health concern afflicting 3 million people in the United States
every year [80, 81]. Injury from sepsis occurs as a result of an uncontrolled inflammatory
response [82]. The role of T- and B-cells in sepsis was first demonstrated in Rag1− / − mice,
which were shown to succumb more readily to polymicrobial sepsis [83]. Interestingly,
repletion of Rag1− / −mice with B-cells improves survival, demonstrating that B-cell
function in the absence of T cell-dependent Abs is important for sepsis outcome [84]. An
appropriate immune response is necessary to confer protection against sepsis, while the lack
of a first line of defense may exacerbate disease pathogenesis. Intriguingly, a recent study
demonstrated the lack of B-cells in µMT− / − mice resulted in increased mortality, similar to
Rag1− / − mice [84]. However, T-cell-deficient TCRαβ − / − mice did not display increased
susceptibility to sepsis-induced mortality when compared with WT mice. These findings
suggest an essential role for B-cells and innate immune responses in sepsis.
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To evaluate the role of natural IgM in the immediate response against sepsis, one of the first
studies conducted was in mutant mice deficient in secreted (s)IgM in an acute peritonitis
model induced by cecal ligation and puncture (CLP). This study revealed a significant
increase in mortality in sIgM-deficient mice as compared with their WT counterparts [85].
This increased susceptibility was associated with a reduced level of tumor necrosis factor-α
(TNF-α), a decreased neutrophil infiltration to clear peritoneal bacteria, and elevated levels
of endotoxin and proinflammatory cytokines in the circulation. Conversely, resistance to
CLP by sIgM-deficient mice was restored by reconstitution with polyclonal IgM from
normal mouse serum [85]. The study also revealed the role of antibody specificity, inasmuch
as administration of a monoclonal IgM specific to phosphatidylcholine (PtC) had a
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protective effect but a monoclonal IgM specific to phosphorylcholine (PC) was not
protective. These findings suggest a critical role of natural IgM for immediate defense
against severe bacterial infection, and thus suggest a role for B-1a cells in responding to
sepsis [85]. The consequences of sIgM in the murine sepsis model can be correlated with
clinical findings where specific changes of circulating IgM occur when patients with severe
sepsis progress into septic shock [86]. In this hospital-based study, paired comparisons at
distinct time points over the course of sepsis showed IgM was decreased only when patients
deteriorated from severe sepsis to septic shock. Consequently, the study also revealed that
production of IgM by B-cells was significantly lower at all stages of sepsis compared with
healthy controls [86]. Considering altered circulatory IgM levels as one of the fate
determining factors for patients with sepsis, a clinical trial was conducted by administration
of an IgM-enriched Ig preparation, known as Pentaglobin therapy, monitoring the
progression of organ failure and septic shock in patients with severe sepsis [87]. Although
like other clinical trials Pentaglobin therapy did not produce an improvement in any of the
outcome measures of patients with severe sepsis, it was shown to have promising inhibitory
effects on TNF-α production in vitro [87]. Since B-1 cells are known to contribute to the
homeostasis of serum IgM levels, assessment of the status of B-1a cells in terms of their
frequencies and numbers at different organs may establish a link between decreased serum
levels of IgM and B-1a cell contents during sepsis.

Author Manuscript

The direct role of B-1 cells to temper endotoxemic inflammatory responses has been
demonstrated recently by utilizing B-1 cell deficient Xid mice which showed increased
mortality over WT counterparts during endotoxemia [88]. Increased levels of proinflammatory cytokines, TNF-α, IL-6, and decreased levels of IL-10 were found in plasma,
lung, and gut in Xid mice after sepsis [88]. By utilizing macrophage and B-1a cell co-culture
experiments the investigators demonstrated that the immunomodulatory function of B-1a
cells in sepsis could be mediated through IL-10 production [88]. However, apart from IL-10mediated immune regulation by B-1a cells, other relevant work suggests that the protective
role of B-1a cells in sepsis could also be mediated through natural IgM production to
neutralize endotoxin [89]. Reconstitution of Bruton’s tyrosine kinase (Btk)-deficient mice,
which lack B-1a cells and have reduced levels of lgG3 and IgM, with purified normal mouse
IgM dramatically enhances their ability to clear endotoxin [89]. The pathogenesis of sepsis
may also arise due to uncontrolled accumulation of apoptotic cells in organs; it is therefore
speculated that B-1 cell natural IgM could facilitate the clearance of apoptotic cells by
phagocytes, which might aid in the amelioration of sepsis.
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In response to LPS stimulation peritoneal B-1a cells proliferate, migrate to the spleen, and
give rise to the GM-CSF+ IRA B-cell population [51]. In a murine model of sepsis, mice
with a B-cell-restricted deficiency in GM-CSF showed increased neutrophil infiltration to
the peritoneum [51]. However, these neutrophils had impaired phagocytic activity, and the
mice experienced a severe cytokine storm and died. This suggests that GM-CSF-producing
B-cells contribute to bacterial clearance by promoting neutrophil phagocytic function [51].
In contrast to identification of a beneficial role of IRA B-cells in sepsis, a recent report also
revealed that these cells produce IL-3, which might degrade sepsis outcomes [52]. IL-3
production by these cells enhanced emergency myelopoiesis leading to uncontrolled
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cytokine storm during sepsis [52]. By contrast, although IL-3 production by IRA B-cells was
shown to be detrimental in systemic inflammation due to accelerated emergency
myelopoesis, a recent study revealed that improved emergency myelopoiesis could be
beneficial for survival in neonatal sepsis [90].
Atherosclerosis
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Atherosclerosis is a chronic inflammatory disorder, in which leukocytes infiltrated within
the atherosclerotic vessels augment inflammation by increasing the expression of adhesion
molecules, cytokines, matrix metalloproteinases, and tissue factor [91]. Inflammation during
atherosclerosis is associated with increased levels of oxidized low-density lipoproteins
(OxLDL) trapped in the arterial walls [92]. B-1a cells have been shown to be
atheroprotective by their production of natural IgM that eliminate OxLDL as well as
apoptotic and necrotic cells [93]. Healthy individuals contain basal levels of natural IgM
which recognize OxLDL [94]. It has been reported that when atherosclerosis-prone mice
were injected with heat-killed S. pneumonia, they generated high levels of serum antiOxLDL IgM that protect against atherosclerosis [95]. The direct role of natural IgM in
atherosclerosis has also been shown by administration of natural IgM to mice with advanced
atherosclerosis, leading to decreased severity of the disease [96]. Conversely, mice deficient
in secretory IgM or C1q developed increased atherosclerotic lesions as compared to mice
with normal levels of serum IgM or C1q [reviewed in 33]. Since B-1a cells maintain overall
resting serum IgM levels, their role in protection against atherosclerosis can easily be
understood. In support of the above statement recent literature reviews also indicate that
B-1a cells and B-1a cell-derived natural IgM are protective against atherosclerosis [93].
However, in addition to natural IgM, B-1a cells may also spontaneously secrete IL-10 and
adenosine, which inhibit inflammation produced by activated macrophages and T-cells
present in atherosclerotic lesions [93]. Moreover, the B-1a cells can undergo in vivo
expansion induced by self-antigens or IL-9 administration, which could serve as a potential
therapeutic strategy to inhibit atherosclerosis [reviewed in 93].
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Beyond reports that suggest natural antibodies, IL-10 and adenosine produced by B-1a and
B10 cells may counteract inflammation that is part of atherosclerotic disease, a recent study
demonstrated GM-CSF secreting IRA B-cells did not show any protection in atherosclerosis
[97]. In response to a high cholesterol diet, IRA B-cell numbers in mice and humans
increased preferentially in secondary lymphoid organs via Myd88-dependent signaling [97].
However, this increase may contribute to pathology inasmuch as mixed chimera mice
lacking B-cell derived GM-CSF developed smaller lesions with fewer macrophages and
effector T-cells. Mechanistically, IRA B-cells promote the expansion of classical dendritic
cells, which then generate IFNγ-producing Th1 cells. This IRA B-cell-dependent Th1
skewing manifests in an IgG1 to IgG2c isotype switch in the immunoglobulin response
against oxidized lipoproteins. Thus, the IRA B-cells alter adaptive immune processes and
shift leukocyte responses toward a Th1-associated milieu that aggravates atherosclerosis
[97]. However, since these IRA B-cells still secrete natural IgM which could be beneficial,
their role in atherosclerosis needs to be further evaluated.

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Aziz et al.

Page 11
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Inflammatory bowel disease (IBD), along with its two clinical subtypes, Crohn’s disease
(CD) and ulcerative colitis (UC) are characterized by chronic and relapsing forms of severe
gastrointestinal tract inflammation [98]. In the United States, it is currently estimated that
about 1–1.3 million people suffer from IBD [99]. The pivotal immunoregulatory role of
B-1a cells in protection against colitis has recently been shown by utilizing TCRα −- mice
[100]. Under specific pathogen-free (SPF) conditions, TCRα − / − mice were found to be
more susceptible to develop colitis than similar animals in a conventional facility [100]. Of
note, the mice kept in the conventional facility had increased levels of natural IgM produced
by B-1a cells to suppress colitis initiation. Conversely, B-cell-deficient Igμ (Igh6) and
TCRα double-knockout (αμDKO) mice housed in a conventional facility continued to
develop severe colitis, suggesting a protective role for B-1a cells. Further, when these
αμDKO mice within the conventional facility were adoptively transferred with peritoneal
B-1a cells isolated from TCRα −/- mice they became protected against colitis [100].
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IL-10 is known to play an immunoregulatory role during colitis, as mice deficient in IL-10
develop spontaneous colitis with many similarities to human Crohn’s disease [101]. The
therapeutic potential of IL-10 producing regulatory B-cells or B10 cells in experimental
colitis has been demonstrated in recent reports. Studies in CD19− / − mice, which have few,
if any B10 cells, revealed more severe dextran sulfate sodium-induced intestinal injury than
in WT animals [102]. Remarkably, adoptive transfer of B10 cells isolated from the spleens
of WT mice reduced inflammation in CD19− / − mice by improving the physiological,
histological, and immunological parameters in an IL-10-dependent manner, which may
provide new insights and therapeutic approaches for treating ulcerative colitis [102].
Consistent with findings in the CD19−/- mice, G protein α inhibitory subunit 2 knockout
(Gαi2− / −) mice, which have significantly reduced numbers of B-1a, B10, MZ, and T2 Bcells can spontaneously develop IBD [103]. Besides the protective role of splenic B10 cells
in colitis, a recent report characterized peritoneal cavity B10 cells in terms of spontaneous or
inducible IL-10 production and validated their function in colitis [104]. Importantly, these
IL-10 producing peritoneal cavity B-cells significantly reduced disease severity in
spontaneous and induced models of colitis by regulating neutrophil infiltration, colitogenic
CD4+ T-cell activation, and proinflammatory cytokine production during the onset of colitis,
thereby helping to maintain homeostasis within gastrointestinal tissues and the immune
system. A recent report regarding adenosine-producing CD73 expressing B-1a cells showed
protection against chemically induced colitis in mice [57]. Collectively, these studies clearly
demonstrate the potential therapeutic role of B-1a, B10 and Breg cells during intestinal
inflammation via IgM, IL-10, and adenosine production.
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Autoimmune diseases
Autoimmune diseases can affect almost any part of the body and typically have a major
inflammatory component [105]. Different functions of B-cells, especially the secretion of
autoantibodies, presentation of autoantigens, and secretion of inflammatory cytokines
contribute to autoimmune diseases [106]. Considering the ability of B-1a cells to present
antigen and skew T-cells towards Th17 differentiation, they may promote autoimmunity if
their immunosuppressive functions as mediated by IL-10 and adenosine production become
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dysfunctional [32, 107]. The autoreactive nature of natural IgM speeds the elimination of
dead and dying cells and cellular debris [108]. By contrast, mice lacking natural IgM are
prone to accelerated development of IgG autoantibodies and more severe autoimmune
diseases, presumably because antigens and inflammation associated with apoptotic cell
debris stimulate B-2 cell responses when not properly cleared in a timely fashion [108].
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The importance of IL-10 producing regulatory B-cells for controlling experimental
autoimmune encephalomyelitis (EAE), a Th1-mediated autoimmune disease of the central
nervous system (CNS), has been reported recently [109, 110]. The role of B-1a cells as well
as IL-10 producing regulatory B-cells in controlling the development of EAE has been
examined in CD19− / − mice, which are deficient in B-1a cells [110]. The study showed that
the greater severity of EAE in CD19− / − mice as compared with WT animals was associated
with polarized Th1 cytokines in the inflamed CNS, causing exaggerated neuroinflammation
[110].
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Interleukin-35 belongs to the IL-12 family of cytokines and represents a potential
therapeutic target in autoimmune, inflammatory, and infectious diseases. The
immunosuppressive effect of IL-35 is mediated through regulatory T- and B-cells [111].
Wang et al. recently showed that IL-35 induced Breg cells to secrete both IL-10 and IL-35
[4]. Injection of recombinant IL-35 or IL-35+ Breg cells into mice after induction of
experimental autoimmune uveitis (EAU), a mouse model of autoimmune eye disease,
resolved inflammation by suppressing effector Th1 and Th17 cell responses and inducing
Foxp3+ Treg cells [4]. Beside the work on IL-35+ Breg cell-mediated protection against EAU,
a supportive study by Shen et al. identified TLR-4 and CD40L co-stimulation as the main
driver of B-cell-mediated IL-35 production in a mouse model of EAE [112]. The importance
of IL-35+ Breg cells was demonstrated in mice lacking B-cell specific IL-35, which resulted
in substantially worse outcomes in EAE [112]. B-cells lacking IL-35 expressed higher levels
of co-stimulatory molecules and functioned as more potent antigen-presenting cells to Tcells compared to IL-35 expressing B-cells, leading to stronger inflammatory T-cell
responses [112]. Beyond IL-35, a recent study demonstrated that PD-L2+ B-1a cells may
play a role in opposing the development of autoimmunity not only by PD-1/PD-L2-mediated
immunosuppression but also by their specific natural IgM production [39]. Collectively
these features reveal the importance of B-1a and Breg cells for protection against
autoimmune diseases by secretion of imunoregulatory molecules.
Obesity and diabetes mellitus
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Obesity is associated with a state of chronic, but low-grade inflammation [113]. IL-10secreting regulatory B-cells have an anti-inflammatory role in murine obesity [114].
Nishimura, et al. recently identified a distinct set of IL-10 secreting B-cells, which
negatively regulate adipose tissue inflammation [115]. The phenotype of these IL-10
secreting B-cells from subcutaneous and epididymal adipose tissue was identified as
CD1dloCD5−/loCD11bloCD21/
CD35loCD23−/loCD25+CD69+CD72hiCD185−CD196+IgM+IgD+, which was phenotypically
distinct from other IL-10 secreting B-cells isolated from spleen and peritoneal cavity
expressing CD1dhiCD5+ [115]. It has been shown that with a deficiency of these distinct

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Aziz et al.

Page 13

Author Manuscript
Author Manuscript

IL-10 producing B-cells, infiltration of pathogenic T-cells and macrophages in adipose
tissue of obese mice was higher than in control animals [118]. In addition, obesity is closely
linked to other metabolic diseases such as insulin resistance and type-2 diabetes mellitus
where regulatory B-cells play crucial roles [115]. Studies using lean mice lacking Breg cells
exhibited insulin resistance and impaired fasting glucose clearance [118]. A recent study
revealed that B-cells secrete a short peptide derived from proteolytic cleavage of
adiponectin, which negatively regulates T-cell trafficking across inflammed endothelium
[116]. Interestingly, patients with type-1 diabetes (T1D) had reduced serum levels of the
adiponectin -derived short peptide, which implicates B-cells in controlling T1D
pathogenesis [116]. Moreover, protection from T1D requires B-cell-derived IL-10
production, because transfusion of activated NOD-IL-10− / − B-cells does not confer
protection from T1D in NOD recipients [117]. Thus, evaluation of B-1a cells as well as Breg
cells in various inflammatory diseases is likely to provide potential therapeutic possibilities
(Fig. 1).

Conclusions and perspectives
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Three decades of research on B-1 cells along with related B-cells and subsets, demonstrates
that B-1 cells are indispensable for protection against various inflammatory diseases and for
maintaining normal homeostasis. Although ample studies have been carried-out to
characterize phenotypic, ontogenic, and functional profiles, additional work is still required
to understand the complexity of how B-1 cells are involved in host pathogen interactions in
various inflammatory diseases. The role of B-1 cells in cerebral, intestinal or hepatic
ischemia, and other systemic inflammatory diseases is yet to be evaluated and could open
new fields of research. Apart from natural IgM, current studies also focus on identifying
novel molecules that are being secreted by B-1 cells to modulate the inflammatory milieu.
Further study of novel cellular interactions involving B-1 cells and B-1 cell trafficking in
various organs after inflammation may resolve several unanswered questions of disease
pathogenesis. A clear dissection of B-1 cell biology will help to develop novel approaches
for the prevention of infectious, autoimmune, and inflammatory diseases.
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Breg

regulatory B-cells

GM-CSF
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IRA
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MHC

major histocompatibility complex

STAT3

signal transducer and activator of transcription 3

NF-κB

nuclear factor-κB

PC

phosphorylcholine

PtC

phosphatidylcholine

PD-1

programmed death-1

PD-L1

programmed death-ligand 1

PD-L2

programmed death-ligand 2

TLR-4

toll-like receptor-4

ENPP1

ectonucleotide pyrophosphatase phosphodiesterase 1

ATP

adenosine triphosphate

PMA

phorbol 12-myristate 13-acetate

BCR

B-cell receptor

CLP

cecal ligation and puncture

TNF-α

tumor necrosis factor-α

Btk

Bruton’s tyrosine kinase

OxLDL

oxidized low-density lipoprotein

Gαi2

G protein α inhibitory subunit 2-deficient

EAE

experimental autoimmune encephalomyelitis

EAU

experimental autoimmune uveitis

T1D

type-1 diabetes
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Figure 1. Role of B-1 cells in inflammatory diseases
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B-1 cells recognize endogenous antigens and invading pathogens through B-cell receptor
(BCR) or toll-like receptor (TLR)-mediated pathway. Reorganization of Ag causes B-1a
cells to migrate from the peritoneal or pleural cavities to the regional lymph nodes or spleen
where they may become activated to IgM producing B-cells/memory B-cells. The
polyreactive, repertoire skewed natural IgM recognize wide range of endogenous and
exogenous Ag to eliminate from the host thus, reducing systemic inflammation. GM-CSF
secreting IRA B-cells migrate to the spleen and lungs and confer protection against systemic
as well as local S. pneumonia-induced inflammation. By contrast, the IRA B-cells convert
Ly6Clo monocytes to pathogenic Ly6Chi monocytes in the spleen which then traffic to the
atherosclerotic lesions and become atherogenic foam cells, thereby exacerbating
atherosclerosis. Apart from B-1 and IRA B-cells, regulatory B-cells play protective roles
against various systemic, autoimmune and inflammatory bowel disease by producing
immunoregulatory cytokine, IL-10, and natural IgM.
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Phenotype, location and function of B-1 cells, B-1 cell subsets, and B-1 related B-cell subsets
Cell types

Phenotype

Location

Function

B-1a

B220loCD23−

PerC, spleen,
pleural cavity, bone
marrow, intestine

Spontaneously secret polyreactive
natural IgM in an antigen-independent
manner that recognize pathogens,
OxLDL; Promote phagocytic
clearance of apoptotic cells; Th17 cell
differentiation

6, 8

CD5+CD19+
IgMhiIgDlo
CD43+

References

Author Manuscript
Author Manuscript

B-1b

B220loCD23−CD5−
CD19+IgMhiIgDlo
CD43+CD1dmid

PerC, spleen, lung

Produce Abs after encountering Tcell-independent antigens

11

Marginal
zone

B220+CD23−IgMhi
IgDloCD21hi
CD43−CD1dhi

Marginal sinus of
spleen, subcapsular
sinus of lymph
nodes*

Antigen presentation, elicit T-cellindependent immune response

44

Follicular

B220hiCD19+
CD23hiCD1dmid
CD21midIgMloIgDhi

Germinal centers
of spleen

Elicit T-cell-dependent responses to
protein antigens

118

IRA B

IgMhiIgDloCD23lo
CD43+CD93+
VLA4hiCD19hi
CD284+GMCSF+

PerC, spleen,
serosal sites

Secret GM-CSF and regulate IgM
production via GM-CSF axis in an
autocrine manner; induce emergency
myelopoesis by IL-3 production

51, 52

Breg/B10

CD5+CD19hi
CD1d+/hiCD21+
CD23+/−CD43+/−
IgMhiIgDloIL10+

Spleen, PerC,
blood*

Regulate inflammatory responses
through IL-10 production

102

B-1a.PD-L2

B220loCD23−CD5+
CD173(B7-DC)+
IgMhiIgDlo

Spleen, PerC

Repertoire skewed production of PtCbinding VH11 and VH12 Ig which play
key role in immune defense against
bacterial infection

39

B-1a.CD73hi

B220loCD23−
CD73hiCD39+

Spleen, PerC

Produce adenosine in the presence of
substrate and play an
immunomodulatory role during
inflammation

57

B-1a.PC1lo/hi

CD19+CD5+CD23−PC1lo/hi

PerC

Play innate-like or immunoregulatory
function based on natural IgM or IL10 production by PC1 low and high
expressing B-1a subsets, respectively

59

IL-35+ B-1

IgM+CD138hi
CD43+TACI+
CXCR4+CD1dmid
Tim1mid

Spleen

Express anti-inflammatory cytokines
and regulate T-cell-mediated hyper
immunity

4, 112

CD138+
B-1a

B220loCD23−
CD5+CD138+
IgMhiIgDlo

Spleen

Secrete large amounts of natural IgM
which are skewed with respect to Nregion addition, and some aspects of
VH and JH utilization

119

Human B-1

CD3−CD19+CD20+
CD27+CD43+
CD69− CD70−

Umbilical cord and
adult peripheral
blood

Spontaneous natural IgM and IL-10
secretion to regulate inflammation

65, 66
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*

human; PerC, peritoneal cavity; IgM, immunoglobulin M; OxLDL, oxidized low-density lipoprotein; GM-CSF, granulocyte-macrophage colonystimulating factor; PtC, phosphatidylcholine
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